Immunotherapy is a type of cancer treatment that helps the immune system fight cancer. For example, chimeric antigen receptor T cell (CAR-T) therapy is used to target several types of blood cancer. It works by reprogramming patients’ immune cells to target specific tumor cells. In blood cancers, CAR-T therapy works very well, but it can cause extreme responses from the patient’s immune system, which can be life threatening. In solid tumors, CAR-T therapy is much less successful because the tumors secrete molecules into the space surrounding them, which weaken the immune processes that attack cancerous cells.

Stem cells are the master cells of the body. Originating in the bone marrow, they can repair and regenerate the body’s cells. Cancer stem cells play a role in resistance to CAR-T therapy, due – in part – to their ability to renew themselves, but the role of another type of stem cell, called mesenchymal stem cells, was less clear. Mesenchymal stem cells develop into tissues that line organs and blood vessels. Although it is known that mesenchymal stem cells are present in most cancers and play a role in shaping and influencing the space around tumors, their impact on CAR-T therapy has not been studied in depth.

To find out more, Zhang et al. looked at the influence of a protein, called staniocalcin-1 (STC1), on CAR-T therapy, by studying cells grown in the laboratory and human tumor cells that had been implanted in mice.

Zhang et al. found that mesenchymal stem cells reduce the ability of CAR-T therapy to destroy cancer cells and that they needed STC1 to do this successfully. They also increased the expression of molecules that dampen the immune system, and suppressed molecules called inflammasomes, which are an important part of the way the immune system detects disease. Moreover, reducing the amount of STC1 that mesenchymal stem cells expressed restored the effectivity of CAR-T therapy.

This study increases our understanding of the way that mesenchymal stem cells affect CAR-T therapy. It has the potential to open up a new way of improving the efficiency of this treatment and of reducing the harmful side effects that it can cause.

Advances in chimeric antigen receptor modified T cell therapy (CAR-T) in recent years have shown enormous promise in cancer immunotherapy, which has produced unprecedented clinical outcomes, most notably for patients with hematologic malignancies (Singh et al., 2016; Park et al., 2018). Despite the striking achievements, CAR-T therapy is also facing many challenges such as the treatment-related severe toxicity and side effects, including cytokine release syndrome (CRS) and neurotoxicity (Hong et al., 2020; Freyer and Porter, 2020). CRS is the most common acute toxicity associated with an excessive immune response that causes fever, hypotension, and respiratory insufficiency. The neurotoxicity induced by CAR-T therapy exhibits a diverse array of neurologic symptoms such as tremors, expressive aphasia, and impaired attention. The precise mechanism that causes these life-threatening side effects remains unclear (Freyer and Porter, 2020; Jiang et al., 2019). On the other hand, the success of CAR-T therapy in treating solid tumors is still very limited (Martinez and Moon, 2019). Identifying hurdles and potential mechanisms that impede the function of CAR-T cells is of vital importance to expanding its use. The immunosuppressive tumor microenvironment (TME) is one of the obstacles that diminishes the efficacy of CAR-T therapy, especially for solid tumors.

Among the many factors that can modulate TME and immune response, the impact of mesenchymal stem cell (MSC) on CAR-T therapy has been little studied. MSC is a type of adult stem cell with high proliferative activity and multidirectional differentiation capacity. However, MSCs have additional paracrine effects that are believed to underlie their therapeutic functions (Jiang and Xu, 2020). By secreting a variety of cytokines into the tissue microenvironment, it has been known that MSCs can modulate extracellular matrix, promote angiogenesis, and suppress inflammation and apoptosis (Keating, 2012; Wang et al., 2014; Regmi et al., 2019). Some MSC-secreted cytokines, such as stromal cell-derived factor 1 and stem cell factor, play important roles in hematopoietic and immune regulation (Kawaguchi et al., 2019; Markov et al., 2007). In addition, studies suggest that MSCs can modulate the function of monocytic lineages cells, especially macrophages (Németh et al., 2009; YlÖstalo et al., 2012; Choi et al., 2011). Some reports also showed that MSCs could directly affect the functionality and cellular responses of T cells, Tregs, and memory T cells (Cen et al., 2019; Tumangelova-Yuzeir et al., 2019; Luque-Campos et al., 2019).

It was reported that human mesenchymal stem cells (hMSCs) could be activated by lipopolysaccharide (LPS)-stimulated macrophages to increase the expression and secretion of stanniocalcin-1 (STC1) (Oh et al., 2014). STC1 was a mitochondria-related glycoprotein originally identified as a calcium/phosphate regulating hormone in bony fishes, and later on, it was found to be a pleiotropic factor involved in various degenerative diseases such as ocular and renal disease, as well as idiopathic pulmonary fibrosis (Yeung et al., 2012; Ohkouchi et al., 2015). STC1 could improve the cell survival and regeneration of MSCs in a paracrine fashion (Ono et al., 2015). There was also evidence suggesting that STC1 played an oncogenic role in various types of tumors (Du et al., 2011; Liu et al., 2010). Based on a retrospective study of ~1500 clinical samples, it was concluded that high STC1 expression is associated with the poor clinical outcome of breast cancer (Chang et al., 2015). It was proved that STC1 is involved in several oxidative and cancer-related signaling pathways, such as NF-κB, extracellular-signal-regulated kinase (ERK), and c-Jun NH(2)-terminal kinase (JNK) pathways (Nguyen et al., 2009; Chan et al., 2017). The expression and secretion of STC1 in cancer tissue can be stimulated by external stimuli, including external cytokines and oxidative stress (Nguyen et al., 2009). Under hypoxia conditions, STC1 could be modulated by Hypoxia-inducible factor-1 (HIF-1) to facilitate the reprogramming of tumor metabolism from oxidative to glycolytic metabolism (Yeung et al., 2005). STC1 was also reported to participate in the process of epithelial-to-mesenchymal transition, which is associated with tumor invasion and the reshape of the tumor microenvironment, as well as increasing therapy resistance (Pastushenko and Blanpain, 2019).

Considering the pleiotropic role of STC1, especially its intercellular linkage between MSCs, cancer cells, and macrophage stimulation, it is interesting to know what role it plays in connection to the functions of MSC in TME. Therefore, we generated a stable STC1 knockdown MSC cell line. With a cell co-culture model containing CAR-T cells, hMSCs, macrophages, and Pfeiffer lymphoma cells to partially mimic the tumor microenvironment together with a xenograft mice model, here we studied the impacts of MSC on CAR-T efficacy and the potential immune response change in the presence and absence of STC1.

Stem cells are believed to play critical roles in resistance to cancer therapy, which is a major contributor to poor treatment responses and tumor relapse. Previous studies have been mainly focused on the role of cancer stem cells. In the current study, we presented evidences that the presence of MSCs in TME may also be an important source of cancer treatment resistance. By modulating TME, MSCs showed a strong suppressive function on CAR-T efficacy toward lymphoma cells, and interestingly, the presence of the STC1 gene played a critical role.

The role of STC1 in cancer is paradoxical. Some reports showed that it exerts an oncogenic role, whereas other studies suggested the opposite (Chen et al., 2019). The aberrant expression of STC1 has been reported to impact various types of cancer, such as triggering tumor angiogenesis by upregulating the expression of VEGF in gastric cancer cells (He et al., 2011), causing tumorigenesis and poor clinical outcomes in ovarian, colorectal, and lung cancers (Yeung et al., 2012; Chen et al., 2019). To date, the potential roles of STC1 in immunotherapy are still largely unknown. Here, we demonstrated that the presence of STC1 is critical for MSC to exert its immunosuppressive role by inhibiting cytotoxic T cell subsets, activating some key immune suppressive/escape mechanisms, and crosstalk with other immune cells.

First, a significant downregulation of CD8⁺ T Cells together with the upregulation of CD4⁺ T helper cell subsets and Tregs indicated that the suppressed CAR-T efficacy was at least partially associated with MSC’s function in modulating the proliferation of different T-cell subsets. Since the suppression of CD8⁺ T cells was completely abrogated if knockdown STC1 in MSCs, it is clear that STC1 played a key role here. Moreover, considering that STC1 is secreted into the extracellular matrix in a paracrine manner, MSCs’ modulation of the T cell subsets is most likely indirectly via altered cytokine expression or other secondary molecules activated by STC1. In line with our study, it was recently reported that STC-1 negatively correlates with immunotherapy efficacy and T cell activation by trapping calreticulin, which abrogates membrane calreticulin-directed antigen presentation function and phagocytosis (Lin et al., 2021).

The presence of MSCs also stimulated the expression of IDO and PD-L1, two important immune-suppressive molecules. Upregulation of IDO is an endogenous feedback mechanism controlling excessive immune responses, which can be produced both by tumor cells and macrophages (Uyttenhove et al., 2003). IDO-mediated formation of immunosuppressive metabolites can inhibit T-cell proliferation and induce T-cell death through the dioxin receptor (Opitz et al., 2011; Frumento et al., 2002). PD-L1 is a well-characterized molecule of the major escape mechanism of immunotherapy by inhibiting PD-1-mediated effector T cell function and downregulating antigen tolerance (Ribas and Hu-Lieskovan, 2016). There have been numerous studies reporting the bidirectional interactions between MSCs and cancer cells, resulting in regulating the expression of PD-L1 on the surface of various cancer cells or TME (Aboulkheyr and Bigdeli, 2022; Krueger et al., 2019; O’Malley et al., 2018; Sun et al., 2018). Importantly, here we demonstrated that the upregulated expression of both IDO and PD-L1 by MSCs was much reduced if the STC1 gene was knockdown.

The paracrine activity of MSCs is now widely recognized as an important cellular mechanism to communicate with immune cells and various other cell types in TME (Teixeira et al., 2013). Consistent with previous studies, we found that the addition of hMSCs to the co-culture cell model suppressed the formation of NLRP3 inflammasome in macrophages as determined by the downregulation of some key proteins including IL-1β, the activated caspase-1, and AIM. It was reported that CD4⁺ T cells could inhibit inflammasome-mediated caspase-1 activation and IL-1β release through TNF ligands or by interferon signaling (Guarda et al., 2009). Therefore, the modulation of T-cell subsets and activation of the NLRP3 inflammasome by hMSC appear to be closely connected. Since NLRP3 inflammasome is a key factor in the neuroinflammation onset in CNS injuries (Menu and Vince, 2011), the suppression of NLRP3 inflammasome by hMSC may be potentially beneficial in reducing the exacerbated immune responses associated with CAR-T therapy.

The formation of the NLRP3 inflammasome was reported to be through NF-κB-dependent transcription of IL-1β, IL-18, and NLRP3, whereas its activation is triggered by extracellular stimuli such as lysosomal permeability, potassium efflux, and oxidative stress (Kelley et al., 2019). It has been proved that the expression and secretion of STC1 in multiple cell lines can be stimulated by external stimuli, including cytokines and oxidative stress (Nguyen et al., 2009). Considering that exogenous STC1 could be internalized by macrophages within 10 min and localizes to mitochondria and played a suppressing role in ROS generation (Wang et al., 2009), we speculated that the inhibition of NLRP3 inflammasome formation might be a feedback mechanism that occurred between macrophages and hMSC. It was reported that LPS-stimulated macrophages do stimulate the expression and secretion of STC1 in hMSCs (Oh et al., 2014). Our data further demonstrated that knockdown of STC1 deprived the function of hMSC in suppressing all the three markers used in the current study in determining NLRP3 inflammasome formation, as well as the suppression of mitochondria ROS production. These data support the idea that a feedback regulation mechanism exists between hMSC and macrophages during CAR-T therapy.

Using the Xenograft mice model, we confirmed that the tumor-killing efficacy of CAR-T could also be inhibited by hMSCs in vivo, whereas knockdown of STC1 effectively abolished the inhibition. Immunohistochemical data indicated that the downregulation of CD8⁺ T cells, upregulation of CD4⁺ T helper cell subsets, and Tregs were all dependent on the function of STC1. Need to note that the amount of the injected hMSCs was much higher than that of the in vivo situation. Nevertheless, the results give a clear indication that STC1 is critical for the immune-suppressive function of hMSC.

In summary, the present study revealed a significant impact of hMSC in suppressing CAR-T efficacy and provided evidence that the STC1 gene played a critical role in the regulation of various immune-suppressive mechanisms. A speculative schema of the signaling and interactions among hMSC, macrophage, CAR-T, and tumor cells based on our current data is shown in Figure 5. In this model, activated macrophages or stress signals during CAR-T therapy may prompt MSCs to secret STC-1 into the extracellular matrix of TME, serving as a pleiotropic factor to negatively impact the function of T cells and stimulate the expression of molecules that inactivate immune responses, ultimately providing an immunosuppressive effect of MSC. While further studies are needed to understand the detailed molecular interactions underlying, the findings we presented here are no doubt that would have potential clinical applications toward improving the efficiency of CAR-T therapy as well as reducing the excessive toxicity by modulating the level of STC1 in TME.

Figure 5

Download asset Open asset

All data generated or analysed during this study are included in the manuscript. Source data files have been provided for Figures 1, 2, 3 and 4.

1. 1. Aboulkheyr H
   2. Bigdeli B

   (2022) Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells

   Journal of Cellular Physiology 236:3918–3928.

   https://doi.org/10.1002/jcp.30135

   • Google Scholar
2. 1. Cen S
   2. Wang P
   3. Xie Z
   4. Yang R
   5. Li J
   6. Liu Z
   7. Wang S
   8. Wu X
   9. Liu W
   10. Li M
   11. Tang S
   12. Shen H
   13. Wu Y

   (2019) Autophagy enhances mesenchymal stem cell-mediated CD4⁺ T cell migration and differentiation through CXCL8 and TGF-β1

   Stem Cell Research & Therapy 10:265.

   https://doi.org/10.1186/s13287-019-1380-0

   • PubMed
   • Google Scholar
3. 1. Chan KKS
   2. Leung CON
   3. Wong CCL
   4. Ho DWH
   5. Chok KSH
   6. Lai CL
   7. Ng IOL
   8. Lo RCL

   (2017) Secretory stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway

   Cancer Letters 403:330–338.

   https://doi.org/10.1016/j.canlet.2017.06.034

   • PubMed
   • Google Scholar
4. 1. Chang ACM
   2. Doherty J
   3. Huschtscha LI
   4. Redvers R
   5. Restall C
   6. Reddel RR
   7. Anderson RL

   (2015) Stc1 expression is associated with tumor growth and metastasis in breast cancer

   Clinical & Experimental Metastasis 32:15–27.

   https://doi.org/10.1007/s10585-014-9687-9

   • PubMed
   • Google Scholar
5. 1. Chen F
   2. Zhang Z
   3. Pu F

   (2019) Role of stanniocalcin-1 in breast cancer

   Oncology Letters 18:3946–3953.

   https://doi.org/10.3892/ol.2019.10777

   • PubMed
   • Google Scholar
6. 1. Choi H
   2. Lee RH
   3. Bazhanov N
   4. Oh JY
   5. Prockop DJ

   (2011) Anti-inflammatory protein TSG-6 secreted by activated mscs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages

   Blood 118:330–338.

   https://doi.org/10.1182/blood-2010-12-327353

   • PubMed
   • Google Scholar
7. 1. DeNardo DG
   2. Ruffell B

   (2019) Macrophages as regulators of tumour immunity and immunotherapy

   Nature Reviews. Immunology 19:369–382.

   https://doi.org/10.1038/s41577-019-0127-6

   • PubMed
   • Google Scholar
8. 1. Du YZ
   2. Gu XH
   3. Li L
   4. Gao F

   (2011) The diagnostic value of circulating stanniocalcin-1 mrna in non-small cell lung cancer

   Journal of Surgical Oncology 104:836–840.

   https://doi.org/10.1002/jso.21948

   • PubMed
   • Google Scholar
9. 1. Freyer CW
   2. Porter DL

   (2020) Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies

   The Journal of Allergy and Clinical Immunology 146:940–948.

   https://doi.org/10.1016/j.jaci.2020.07.025

   • PubMed
   • Google Scholar
10. 1. Frumento G
    2. Rotondo R
    3. Tonetti M
    4. Damonte G
    5. Benatti U
    6. Ferrara GB

    (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase

    The Journal of Experimental Medicine 196:459–468.

    https://doi.org/10.1084/jem.20020121

    • PubMed
    • Google Scholar
11. 1. Guarda G
    2. Dostert C
    3. Staehli F
    4. Cabalzar K
    5. Castillo R
    6. Tardivel A
    7. Schneider P
    8. Tschopp J

    (2009) T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes

    Nature 460:269–273.

    https://doi.org/10.1038/nature08100

    • PubMed
    • Google Scholar
12. 1. He L
    2. Wang T
    3. Gao Q
    4. Zhao G
    5. Huang Y
    6. Yu L
    7. Hou Y

    (2011) Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells

    Journal of Biomedical Science 18:39.

    https://doi.org/10.1186/1423-0127-18-39

    • PubMed
    • Google Scholar
13. 1. Hong M
    2. Clubb JD
    3. Chen YY

    (2020) Engineering CAR-T cells for next-generation cancer therapy

    Cancer Cell 38:473–488.

    https://doi.org/10.1016/j.ccell.2020.07.005

    • PubMed
    • Google Scholar
14. 1. Jiang H
    2. Gao H
    3. Kong J
    4. Song B
    5. Wang P
    6. Shi B
    7. Wang H
    8. Li Z

    (2018) Selective targeting of glioblastoma with egfrviii/EGFR bitargeted chimeric antigen receptor T cell

    Cancer Immunology Research 6:1314–1326.

    https://doi.org/10.1158/2326-6066.CIR-18-0044

    • PubMed
    • Google Scholar
15. 1. Jiang H
    2. Liu L
    3. Guo T
    4. Wu Y
    5. Ai L
    6. Deng J
    7. Dong J
    8. Mei H
    9. Hu Y

    (2019) Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy

    Annals of Hematology 98:1721–1732.

    https://doi.org/10.1007/s00277-019-03685-z

    • PubMed
    • Google Scholar
16. 1. Jiang W
    2. Xu J

    (2020) Immune modulation by mesenchymal stem cells

    Cell Proliferation 53:e12712.

    https://doi.org/10.1111/cpr.12712

    • PubMed
    • Google Scholar
17. 1. Kawaguchi N
    2. Zhang TT
    3. Nakanishi T

    (2019) Involvement of CXCR4 in normal and abnormal development

    Cells 8:185.

    https://doi.org/10.3390/cells8020185

    • PubMed
    • Google Scholar
18. 1. Keating A

    (2012) Mesenchymal stromal cells: new directions

    Stem Cell 10:709–716.

    https://doi.org/10.1016/j.stem.2012.05.015

    • PubMed
    • Google Scholar
19. 1. Kelley N
    2. Jeltema D
    3. Duan Y
    4. He Y

    (2019) The NLRP3 inflammasome: an overview of mechanisms of activation and regulation

    International Journal of Molecular Sciences 20:3328.

    https://doi.org/10.3390/ijms20133328

    • PubMed
    • Google Scholar
20. 1. Krueger TE
    2. Thorek DLJ
    3. Meeker AK
    4. Isaacs JT
    5. Brennen WN

    (2019) Tumor-infiltrating mesenchymal stem cells: drivers of the immunosuppressive tumor microenvironment in prostate cancer?

    The Prostate 79:320–330.

    https://doi.org/10.1002/pros.23738

    • PubMed
    • Google Scholar
21. 1. Lagadinou ED
    2. Sach A
    3. Callahan K
    4. Rossi RM
    5. Neering SJ
    6. Minhajuddin M
    7. Ashton JM
    8. Pei S
    9. Grose V
    10. O’Dwyer KM
    11. Liesveld JL
    12. Brookes PS
    13. Becker MW
    14. Jordan CT

    (2013) Bcl-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells

    Stem Cell 12:329–341.

    https://doi.org/10.1016/j.stem.2012.12.013

    • PubMed
    • Google Scholar
22. 1. Latha K
    2. Zhang W
    3. Cella N
    4. Shi HY
    5. Zhang M

    (2005) Maspin mediates increased tumor cell apoptosis upon induction of the mitochondrial permeability transition

    Molecular and Cellular Biology 25:1737–1748.

    https://doi.org/10.1128/MCB.25.5.1737-1748.2005

    • PubMed
    • Google Scholar
23. 1. Lin H
    2. Kryczek I
    3. Li S
    4. Green MD
    5. Ali A
    6. Hamasha R
    7. Wei S
    8. Vatan L
    9. Szeliga W
    10. Grove S
    11. Li X
    12. Li J
    13. Wang W
    14. Yan Y
    15. Choi JE
    16. Li G
    17. Bian Y
    18. Xu Y
    19. Zhou J
    20. Yu J
    21. Xia H
    22. Wang W
    23. Alva A
    24. Chinnaiyan AM
    25. Cieslik M
    26. Zou W

    (2021) Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance

    Cancer Cell 39:480–493.

    https://doi.org/10.1016/j.ccell.2020.12.023

    • PubMed
    • Google Scholar
24. 1. Liu G
    2. Yang G
    3. Chang B
    4. Mercado-Uribe I
    5. Huang M
    6. Zheng J
    7. Bast RC
    8. Lin SH
    9. Liu J

    (2010) Stanniocalcin 1 and ovarian tumorigenesis

    Journal of the National Cancer Institute 102:812–827.

    https://doi.org/10.1093/jnci/djq127

    • PubMed
    • Google Scholar
25. 1. Liu D
    2. Xu X
    3. Dai Y
    4. Zhao X
    5. Bao S
    6. Ma W
    7. Zha L
    8. Liu S
    9. Liu Y
    10. Zheng J
    11. Shi M

    (2021) Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment

    Journal for Immunotherapy of Cancer 9:e001466.

    https://doi.org/10.1136/jitc-2020-001466

    • PubMed
    • Google Scholar
26. 1. Luque-Campos N
    2. Contreras-López RA
    3. Jose Paredes-Martínez M
    4. Torres MJ
    5. Bahraoui S
    6. Wei M
    7. Espinoza F
    8. Djouad F
    9. Elizondo-Vega RJ
    10. Luz-Crawford P

    (2019) Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response

    Frontiers in Immunology 10:798.

    https://doi.org/10.3389/fimmu.2019.00798

    • PubMed
    • Google Scholar
27. 1. Markov V
    2. Kusumi K
    3. Tadesse MG
    4. William DA
    5. Hall DM
    6. Lounev V
    7. Carlton A
    8. Leonard J
    9. Cohen RI
    10. Rappaport EF
    11. Saitta B

    (2007) Identification of cord blood-derived mesenchymal stem/stromal cell populations with distinct growth kinetics, differentiation potentials, and gene expression profiles

    Stem Cells and Development 16:53–73.

    https://doi.org/10.1089/scd.2006.0660

    • PubMed
    • Google Scholar
28. 1. Martinez M
    2. Moon EK

    (2019) Car T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment

    Frontiers in Immunology 10:128.

    https://doi.org/10.3389/fimmu.2019.00128

    • PubMed
    • Google Scholar
29. 1. Menu P
    2. Vince JE

    (2011) The NLRP3 inflammasome in health and disease: the good, the bad and the ugly

    Clinical and Experimental Immunology 166:1–15.

    https://doi.org/10.1111/j.1365-2249.2011.04440.x

    • PubMed
    • Google Scholar
30. 1. Minai L
    2. Yeheskely-Hayon D
    3. Yelin D

    (2013) High levels of reactive oxygen species in gold nanoparticle-targeted cancer cells following femtosecond pulse irradiation

    Scientific Reports 3:2146.

    https://doi.org/10.1038/srep02146

    • PubMed
    • Google Scholar
31. 1. Németh K
    2. Leelahavanichkul A
    3. Yuen PST
    4. Mayer B
    5. Parmelee A
    6. Doi K
    7. Robey PG
    8. Leelahavanichkul K
    9. Koller BH
    10. Brown JM
    11. Hu X
    12. Jelinek I
    13. Star RA
    14. Mezey É

    (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin e2–dependent reprogramming of host macrophages to increase their interleukin-10 production

    Nature Medicine 15:42–49.

    https://doi.org/10.1038/nm.1905

    • PubMed
    • Google Scholar
32. 1. Nguyen A
    2. Chang ACM
    3. Reddel RR

    (2009) Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress

    Oncogene 28:1982–1992.

    https://doi.org/10.1038/onc.2009.65

    • PubMed
    • Google Scholar
33. 1. Ninomiya S
    2. Narala N
    3. Huye L
    4. Yagyu S
    5. Savoldo B
    6. Dotti G
    7. Heslop HE
    8. Brenner MK
    9. Rooney CM
    10. Ramos CA

    (2015) Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

    Blood 125:3905–3916.

    https://doi.org/10.1182/blood-2015-01-621474

    • PubMed
    • Google Scholar
34. 1. Oh JY
    2. Ko JH
    3. Lee HJ
    4. Yu JM
    5. Choi H
    6. Kim MK
    7. Wee WR
    8. Prockop DJ

    (2014) Mesenchymal stem/stromal cells inhibit the NLRP3 inflammasome by decreasing mitochondrial reactive oxygen species

    Stem Cells 32:1553–1563.

    https://doi.org/10.1002/stem.1608

    • PubMed
    • Google Scholar
35. 1. Ohkouchi S
    2. Ono M
    3. Kobayashi M
    4. Hirano T
    5. Tojo Y
    6. Hisata S
    7. Ichinose M
    8. Irokawa T
    9. Ogawa H
    10. Kurosawa H

    (2015) Myriad functions of stanniocalcin-1 (STC1) cover multiple therapeutic targets in the complicated pathogenesis of idiopathic pulmonary fibrosis (IPF)

    Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 9:91–96.

    https://doi.org/10.4137/CCRPM.S23285

    • PubMed
    • Google Scholar
36. 1. O’Malley G
    2. Treacy O
    3. Lynch K
    4. Naicker SD
    5. Leonard NA
    6. Lohan P
    7. Dunne PD
    8. Ritter T
    9. Egan LJ
    10. Ryan AE

    (2018) Stromal cell PD-L1 inhibits CD8+ T-cell antitumor immune responses and promotes colon cancer

    Cancer Immunology Research 6:1426–1441.

    https://doi.org/10.1158/2326-6066.CIR-17-0443

    • Google Scholar
37. 1. Ono M
    2. Ohkouchi S
    3. Kanehira M
    4. Tode N
    5. Kobayashi M
    6. Ebina M
    7. Nukiwa T
    8. Irokawa T
    9. Ogawa H
    10. Akaike T
    11. Okada Y
    12. Kurosawa H
    13. Kikuchi T
    14. Ichinose M

    (2015) Mesenchymal stem cells correct inappropriate epithelial-mesenchyme relation in pulmonary fibrosis using stanniocalcin-1

    Molecular Therapy 23:549–560.

    https://doi.org/10.1038/mt.2014.217

    • PubMed
    • Google Scholar
38. 1. Opitz CA
    2. Litzenburger UM
    3. Sahm F
    4. Ott M
    5. Tritschler I
    6. Trump S
    7. Schumacher T
    8. Jestaedt L
    9. Schrenk D
    10. Weller M
    11. Jugold M
    12. Guillemin GJ
    13. Miller CL
    14. Lutz C
    15. Radlwimmer B
    16. Lehmann I
    17. von Deimling A
    18. Wick W
    19. Platten M

    (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

    Nature 478:197–203.

    https://doi.org/10.1038/nature10491

    • PubMed
    • Google Scholar
39. 1. Park JH
    2. Rivière I
    3. Gonen M
    4. Wang X
    5. Sénéchal B
    6. Curran KJ
    7. Sauter C
    8. Wang Y
    9. Santomasso B
    10. Mead E
    11. Roshal M
    12. Maslak P
    13. Davila M
    14. Brentjens RJ
    15. Sadelain M

    (2018) Long-term follow-up of cd19 car therapy in acute lymphoblastic leukemia

    The New England Journal of Medicine 378:449–459.

    https://doi.org/10.1056/NEJMoa1709919

    • PubMed
    • Google Scholar
40. 1. Pastushenko I
    2. Blanpain C

    (2019) Emt transition states during tumor progression and metastasis

    Trends in Cell Biology 29:212–226.

    https://doi.org/10.1016/j.tcb.2018.12.001

    • PubMed
    • Google Scholar
41. 1. Philip B
    2. Kokalaki E
    3. Mekkaoui L
    4. Thomas S
    5. Straathof K
    6. Flutter B
    7. Marin V
    8. Marafioti T
    9. Chakraverty R
    10. Linch D
    11. Quezada SA
    12. Peggs KS
    13. Pule M

    (2014) A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

    Blood 124:1277–1287.

    https://doi.org/10.1182/blood-2014-01-545020

    • PubMed
    • Google Scholar
42. 1. Qiao C
    2. Xu W
    3. Zhu W
    4. Hu J
    5. Qian H
    6. Yin Q
    7. Jiang R
    8. Yan Y
    9. Mao F
    10. Yang H
    11. Wang X
    12. Chen Y

    (2008) Human mesenchymal stem cells isolated from the umbilical cord

    Cell Biology International 32:8–15.

    https://doi.org/10.1016/j.cellbi.2007.08.002

    • PubMed
    • Google Scholar
43. 1. Regmi S
    2. Pathak S
    3. Kim JO
    4. Yong CS
    5. Jeong JH

    (2019) Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives

    European Journal of Cell Biology 98:151041.

    https://doi.org/10.1016/j.ejcb.2019.04.002

    • PubMed
    • Google Scholar
44. 1. Ribas A
    2. Hu-Lieskovan S

    (2016) What does PD-L1 positive or negative mean?

    The Journal of Experimental Medicine 213:2835–2840.

    https://doi.org/10.1084/jem.20161462

    • PubMed
    • Google Scholar
45. 1. Singh N
    2. Frey NV
    3. Grupp SA
    4. Maude SL

    (2016) Car T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia

    Current Treatment Options in Oncology 17:28.

    https://doi.org/10.1007/s11864-016-0406-4

    • PubMed
    • Google Scholar
46. 1. Singh N
    2. Hofmann TJ
    3. Gershenson Z
    4. Levine BL
    5. Grupp SA
    6. Teachey DT
    7. Barrett DM

    (2017) Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function

    Cytotherapy 19:867–880.

    https://doi.org/10.1016/j.jcyt.2017.04.001

    • PubMed
    • Google Scholar
47. 1. Sommermeyer D
    2. Hudecek M
    3. Kosasih PL
    4. Gogishvili T
    5. Maloney DG
    6. Turtle CJ
    7. Riddell SR

    (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

    Leukemia 30:492–500.

    https://doi.org/10.1038/leu.2015.247

    • PubMed
    • Google Scholar
48. 1. Sun L
    2. Wang Q
    3. Chen B
    4. Zhao Y
    5. Shen B
    6. Wang H
    7. Xu J
    8. Zhu M
    9. Zhao X
    10. Xu C
    11. Chen Z
    12. Wang M
    13. Xu W
    14. Zhu W

    (2018) Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mtor-c-myc signal axis

    Cell Death & Disease 9:928.

    https://doi.org/10.1038/s41419-018-0988-9

    • PubMed
    • Google Scholar
49. 1. Teixeira FG
    2. Carvalho MM
    3. Sousa N
    4. Salgado AJ

    (2013) Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?

    Cellular and Molecular Life Sciences 70:3871–3882.

    https://doi.org/10.1007/s00018-013-1290-8

    • PubMed
    • Google Scholar
50. 1. Tumangelova-Yuzeir K
    2. Naydenov E
    3. Ivanova-Todorova E
    4. Krasimirova E
    5. Vasilev G
    6. Nachev S
    7. Kyurkchiev D

    (2019) Mesenchymal stem cells derived and cultured from glioblastoma multiforme increase tregs, downregulate th17, and induce the tolerogenic phenotype of monocyte-derived cells

    Stem Cells International 1:6904638.

    https://doi.org/10.1155/2019/6904638

    • PubMed
    • Google Scholar
51. 1. Turtle CJ
    2. Hanafi L-A
    3. Berger C
    4. Gooley TA
    5. Cherian S
    6. Hudecek M
    7. Sommermeyer D
    8. Melville K
    9. Pender B
    10. Budiarto TM
    11. Robinson E
    12. Steevens NN
    13. Chaney C
    14. Soma L
    15. Chen X
    16. Yeung C
    17. Wood B
    18. Li D
    19. Cao J
    20. Heimfeld S
    21. Jensen MC
    22. Riddell SR
    23. Maloney DG

    (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

    The Journal of Clinical Investigation 126:2123–2138.

    https://doi.org/10.1172/JCI85309

    • PubMed
    • Google Scholar
52. 1. Uyttenhove C
    2. Pilotte L
    3. Théate I
    4. Stroobant V
    5. Colau D
    6. Parmentier N
    7. Boon T
    8. Van den Eynde BJ

    (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

    Nature Medicine 9:1269–1274.

    https://doi.org/10.1038/nm934

    • PubMed
    • Google Scholar
53. 1. Wang Y
    2. Huang L
    3. Abdelrahim M
    4. Cai Q
    5. Truong A
    6. Bick R
    7. Poindexter B
    8. Sheikh-Hamad D

    (2009) Stanniocalcin-1 suppresses superoxide generation in macrophages through induction of mitochondrial UCP2

    Journal of Leukocyte Biology 86:981–988.

    https://doi.org/10.1189/jlb.0708454

    • PubMed
    • Google Scholar
54. 1. Wang Y
    2. Chen X
    3. Cao W
    4. Shi Y

    (2014) Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications

    Nature Immunology 15:1009–1016.

    https://doi.org/10.1038/ni.3002

    • PubMed
    • Google Scholar
55. 1. Yeung HY
    2. Lai KP
    3. Chan HY
    4. Mak NK
    5. Wagner GF
    6. Wong CKC

    (2005) Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells

    Endocrinology 146:4951–4960.

    https://doi.org/10.1210/en.2005-0365

    • PubMed
    • Google Scholar
56. 1. Yeung BHY
    2. Law AYS
    3. Wong CKC

    (2012) Evolution and roles of stanniocalcin

    Molecular and Cellular Endocrinology 349:272–280.

    https://doi.org/10.1016/j.mce.2011.11.007

    • PubMed
    • Google Scholar
57. 1. YlÖstalo JH
    2. Bartosh TJ
    3. Coble K
    4. Prockop DJ

    (2012) Human mesenchymal stem/stromal cells cultured as spheroids are self‐activated to produce prostaglandin E2 that directs stimulated macrophages into an anti‐inflammatory phenotype

    Stem cells 30:2283–2296.

    https://doi.org/10.1002/stem.1191

    • PubMed
    • Google Scholar
58. 1. Zhang R
    2. Wang N
    3. Zhang LN
    4. Huang N
    5. Song TF
    6. Li ZZ
    7. Li M
    8. Luo XG
    9. Zhou H
    10. He HP
    11. Zhang XY
    12. Ma W
    13. Zhang TC

    (2016) Knockdown of DNMT1 and dnmt3a promotes the angiogenesis of human mesenchymal stem cells leading to arterial specific differentiation

    Stem Cells 34:1273–1283.

    https://doi.org/10.1002/stem.2288

    • PubMed
    • Google Scholar
59. 1. Zhang Q
    2. Lu W
    3. Liang CL
    4. Chen Y
    5. Liu H
    6. Qiu F
    7. Dai Z

    (2018) Chimeric antigen receptor (CAR) treg: a promising approach to inducing immunological tolerance

    Frontiers in Immunology 9:2359.

    https://doi.org/10.3389/fimmu.2018.02359

    • PubMed
    • Google Scholar

Author details

1. Rui Zhang

   Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China

   Contribution

   Conceptualization, Formal analysis, Methodology, Writing - original draft

   Competing interests

   No competing interests declared

2. Qingxi Liu

   1. State Key Laboratory of Medicinal Chemical Biology and College of Life Sciences, Nankai University, Tianjin, China
   2. Qilu Institute of Technology, Shandong, China

   Contribution

   Formal analysis, Methodology

   Competing interests

   No competing interests declared

3. Sa Zhou

   College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China

   Contribution

   Methodology

   Competing interests

   No competing interests declared

4. Hongpeng He

   College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China

   Contribution

   Formal analysis

   Competing interests

   No competing interests declared

5. Mingfeng Zhao

   Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China

   Contribution

   Resources, Supervision

   For correspondence

   mingfengzhao@sina.com

   Competing interests

   No competing interests declared

6. Wenjian Ma

   1. Qilu Institute of Technology, Shandong, China
   2. College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China

   Contribution

   Conceptualization, Writing - review and editing

   For correspondence

   ma_wj@tust.edu.cn

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-3392-1549

• 1,481

  views

• 250

  downloads

• 13

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.